Human Vaccines
Stage | Name | Target Disease | Notes |
---|---|---|---|
Approved (Japan) | KD-370 | Pentavalent vaccine against diphtheria, tetanus, pertussis, poliovirus, and Haemophilus influenzae type b | |
Approved (Japan) | ARCT-154 | Self-amplifying mRNA vaccine against COVID-19 | Partnership: CSL Seqirus (Australia) |
Phase Ⅲ (Japan) | ARCT-2301 | Self-amplifying mRNA vaccine against COVID-19 (Bivalent: Original strain and Omicron strain) | Partnership: CSL Seqirus (Australia) |
Phase Ⅲ (Japan) | KD-414 | Inactivated vaccine against COVID-19 (Adults*) | Multi-Regional Clinical Trials * 18-40 years old |
Phase Ⅲ (Japan) | KD-414 | Inactivated vaccine against COVID-19 (Pediatric*) | * 6 months - 11 years old |
Phase Ⅲ (Japan) | KD-414 | Inactivated vaccine against COVID-19 (Pediatric*, Omicron strain) | * 6 months - 12 years old |
Phase Ⅱ (Japan) | KD2-396 | Hexavalent vaccine against diphtheria, tetanus, pertussis, poliovirus, Haemophilus influenzae type b, and Hepatitis B virus | |
Phase Ⅰ (Overseas) | KD-382 | Quadrivalent vaccine against dengue fever |
Veterinary Drugs
Stage | Name | Efficacy Classification | Notes |
---|---|---|---|
Filed (Japan) | ME4137 | Injectable antibacterial drug for cattle | |
Filed (Japan) | ME4137 | Injectable antibacterial drug for swine | |
Filed (Japan) | KD-412 | Vaccine for cattle | Discovered in-house |
Filed (Japan) | MD-22-3002 | Anti-inflammatory drug for cattle, swine and horse | |
Under development | ME4305 | Antibacterial drug for cattle | Discovered in-house |
Under development | MD-22-1001-1 | Injectable antibacterial drug for cattle | |
Under development | ME4406 | Feed Additive | Discovered in-house |
Have a question?
Contact us here.
CONTACT US
Meiji Seika Pharma Co., Ltd.
Based in Japan, we are a leading developer and manufacturer of antibacterial drugs, vaccines and biotech solutions, with a history of over 75 years.
Location
- Headquarters
2-4-16 Kyobashi, Chuo-ku, Tokyo104-8002 Japan